Montelukast vs Pembrolizumab

## Montelukast vs Pembrolizumab: Overview

This comparison examines the pharmacological differences between **Montelukast** and **Pembrolizumab**.

## Mechanism of Action

**Montelukast**: Selective leukotriene D4 receptor antagonist.

**Pembrolizumab**: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

## Pharmacokinetics

**Half-life**: Montelukast — 2.7-5.5 hours; Pembrolizumab — 26 days.

## Chemical Properties

**Molecular Formula**: Montelukast — C35H36ClNO3S; Pembrolizumab — N/A.

**Molecular Weight**: Montelukast — 586.1800 g/mol; Pembrolizumab — N/A.

**Type**: Montelukast — Small molecule; Pembrolizumab — Antibody.